Uruguay's Cannabis Legalization Did Not Increase Youth Use or Risky Consumption ↗
Analysis of 204,730 students found Uruguay's 2013 cannabis legalization was not associated with sustained increases in youth cannabis use, risky use, or frequent use.
Browse more cannabis research, findings, methods, and limitations.
Analysis of 204,730 students found Uruguay's 2013 cannabis legalization was not associated with sustained increases in youth cannabis use, risky use, or frequent use.
Canadian clinical guideline provided GRADE-based recommendations on cannabis effects on fertility, contraception, menopause, and pelvic pain, emphasizing non-stigmatizing care.
Rhesus monkeys given daily THC edibles during pregnancy showed reduced placental blood flow, lower fetal oxygen, decreased amniotic fluid, and placental tissue damage with microinfarctions.
Meta-analysis of 18,000+ paired samples found oral fluid THC tests detect recent cannabis use well but are unreliable for predicting whether blood THC exceeds legal driving limits.
Multilevel school health program across 237 US schools reduced current marijuana use by 23% among 64,838 students, along with reductions in sexual risk and violence.
Systematic review of 6 studies found contingency management effectively reduced cannabis use and achieved abstinence periods in people with psychotic disorders or major depression.
In epileptic rats, THC doubled seizure activity while CBD halved it — and smoked high-THC cannabis increased seizures too, highlighting the importance of cannabinoid ratios.
US cannabis ER visits rose 12% annually from 2006-2014 and continued increasing after 2016. The Midwest had the largest regional surge (36.8%), with notable increases among children and females.
Longitudinal study of 1,084 young adults found 27% increased marijuana use during early COVID-19. Childhood adversity predicted increases among those with low resilience.
Randomized crossover trial in 34 post-stroke patients found nabiximols caused no blood pressure changes, no heart rate changes, and no cardiovascular events during treatment.
6-year Melbourne ER audit found 142 CHS presentations from 67 patients, with 43% returning. All were daily cannabis users. Normal lipase and mild CRP helped distinguish CHS from other causes.
Cannabis industry spent $7M+ lobbying Colorado's legislature over 12 years. Nearly half of reports hid the funder's cannabis connection, and some lobbyists represented alcohol, tobacco, and cannabis simultaneously.
First genomic study of CHS found patients carried significantly more mutations in COMT, TRPV1, CYP2C9, DRD2, and ABCA1 genes, potentially explaining why some heavy users develop CHS while others do not.
First CBG patient survey found users reported it effective for anxiety (51%), pain (41%), and depression (33%), with 74-80% rating it superior to conventional medications and 44% reporting no side effects.
Parents secretly administered a CBD extract to their 4-year-old with brain inflammation, not telling doctors because they assumed the legal product was safe, highlighting risks of unregulated self-prescribing.
Analysis of 881 TikTok cannabis videos found 54% portrayed use positively with 417 million views. 72% used humor. None were age-restricted despite massive youth exposure.
Pilot RCT of 9 trained runners found 300 mg CBD appeared to increase oxygen consumption, exercise pleasure, and VO2max without affecting endurance performance or heart rate.
UK's first medical cannabis registry enrolled 678 patients (mostly chronic pain and anxiety). Preliminary 3-month data showed significant self-reported health improvement with moderate-to-large effect size.
Survey of 344 Canadian MS patients found 65% had tried medical cannabis, primarily for sleep (84%), pain (80%), and spasticity (68%). 74% learned about it outside the healthcare system.
Rat study found prenatal THC caused sex-specific brain lipid disruptions and neuropsychiatric-like behaviors in offspring, with males more persistently affected.
Two-year study found methamphetamine, but not cannabis, predicted worse cognitive outcomes in first-episode schizophrenia patients.
Study of 189 DUI-convicted drivers found those with alcohol interlock devices increased cannabis use, and this substitution persisted after device removal.
Placebo-controlled trial of 150 children with autism found CBD-rich cannabis treatment was not better than placebo for any aspect of sleep.
Lab study found cannabinoid formulations diminished tamoxifen's effectiveness against breast cancer cells, with recreational cannabis ratios showing the largest effect.
Lab model of human sperm development showed cannabis exposure altered DNA methylation at autism-linked and imprinted genes.
First whole-genome sperm methylome study of cannabis exposure found 3,321 altered sites in rats, with changes detectable in offspring and associated with heart enlargement.
Study of 254 veterans with bipolar disorder found current cannabis users had better working memory and functioning than past or non-users, but also higher rates of PTSD and suicidal ideation.
Case report of a 70-year-old cancer patient who developed cannabinoid hyperemesis syndrome from prescribed nabilone, resolving after the drug was stopped.
Systematic review of 17 studies found cannabis cessation is the best CHS treatment, with capsaicin, haloperidol, hot baths, and other options providing symptom relief.
Three-year study of 461 first-episode psychosis patients found those who quit cannabis showed the most attention recovery, reaching scores closest to healthy controls.
Brain imaging study of 60 participants found cannabis-induced psychosis had fewer white matter abnormalities and more gray matter than schizophrenia with cannabis use.
Analysis of 225 participants found reducing cannabis use to lower risk levels was associated with less anxiety, depression, and cannabis-related problems.
Controlled study of 21 people found oral cannabis produced positive urine tests 97.6% of the time versus 59.5% for vaporized cannabis at standard workplace cutoffs.
Case report of a young adult with cannabis use, COVID history, and other complicating factors who developed severe psychosis but achieved complete recovery.
Systematic review of 9 studies found cannabis products reduced hyperactivity, anxiety, sleep problems, and irritability while improving cognition and social interaction in autism.
Meta-analysis of 6 trials with 1,034 patients confirmed CBD reduces seizure frequency by 33% in Dravet syndrome, Lennox-Gastaut, and tuberous sclerosis complex.
Meta-analysis of 57 driving studies found cannabis impairs lane control at levels comparable to low blood alcohol, with cannabis plus alcohol producing the worst impairment.
Survey of 237 endometriosis patients found 72-88% used illicit cannabis despite legal access, with over 60% reporting more than 50% reduction in pain medication use.
Focus groups with 26 Australian women found interest in medicinal cannabis for period pain was high, but cost, stigma, drug driving laws, and prescriber bias blocked access.
Study of 1,023 young adults found perceived parental approval of marijuana and heavy drinking was the strongest predictor of simultaneous alcohol-marijuana use.
NHANES study of 7,159 adults found cannabis use associated with 60-87% higher odds of elevated cardiovascular disease risk scores in a dose-dependent pattern.
Largest fMRI study of cannabis and reward processing (125 participants) found no differences between users and non-users in reward anticipation, with adolescents showing no extra vulnerability.
Analysis of commercial cannabis across 6 US states found strain names and indica/sativa labels do not reliably predict actual chemical content.
Study of 24 cannabis users found smoking high-THC cannabis changed DNA methylation enzyme levels in blood cells within hours, a potential link to psychosis risk.
Mice given THC for 3 days after brain injury recovered working memory and motor function, with increased brain repair factors BDNF, GDNF, and G-CSF.
Genome-wide study of 780,000+ people found shared genetic factor explaining 8.6% of schizophrenia risk, highlighting NCAM1 as a key gene linking smoking, cannabis, and psychosis.
Systematic review of 15 studies found cannabis use associated with aggression in PTSD and psychotic disorders, but causal conclusions cannot be drawn due to methodological limitations.
Survey of 697 medical cannabis patients found 39.3% also used nicotine, with nicotine delivery method predicting cannabis consumption method.
Phase III interim analysis of 59 children with autism found CBD-rich cannabis oil (20:1 CBD:THC) produced no clinically significant blood chemistry changes over 3 months.
Survey of 1,738 students found those with ADHD reported cannabis helped with hyperactivity, impulsivity, and medication side effects, with frequent use moderating executive dysfunction.